Jefferies Financial Group Analysts Reduce Earnings Estimates for AnaptysBio, Inc. (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANABGet Rating) – Jefferies Financial Group lowered their FY2022 earnings estimates for AnaptysBio in a note issued to investors on Wednesday, May 4th. Jefferies Financial Group analyst C. Howerton now forecasts that the biotechnology company will post earnings per share of ($4.10) for the year, down from their prior estimate of ($2.90). Jefferies Financial Group also issued estimates for AnaptysBio’s FY2023 earnings at ($4.30) EPS, FY2024 earnings at ($3.10) EPS, FY2025 earnings at ($2.40) EPS and FY2026 earnings at ($1.50) EPS.

AnaptysBio (NASDAQ:ANABGet Rating) last announced its earnings results on Wednesday, May 4th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.32). AnaptysBio had a negative return on equity of 20.44% and a negative net margin of 143.46%.

A number of other equities research analysts have also recently issued reports on the company. HC Wainwright upped their target price on AnaptysBio from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, March 7th. Guggenheim lowered AnaptysBio from a “buy” rating to a “neutral” rating in a report on Tuesday, March 22nd. Wedbush reiterated a “neutral” rating on shares of AnaptysBio in a report on Monday, March 14th. Zacks Investment Research upgraded AnaptysBio from a “strong sell” rating to a “hold” rating in a report on Thursday, March 17th. Finally, StockNews.com lowered AnaptysBio from a “hold” rating to a “sell” rating in a report on Tuesday, April 26th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $37.25.

Shares of AnaptysBio stock opened at $22.67 on Monday. The stock has a market capitalization of $638.98 million, a P/E ratio of -8.24 and a beta of 0.17. The stock has a 50 day moving average price of $25.52 and a two-hundred day moving average price of $30.02. AnaptysBio has a 12-month low of $20.56 and a 12-month high of $37.89.

A number of large investors have recently made changes to their positions in ANAB. Dorsey Wright & Associates bought a new stake in AnaptysBio in the fourth quarter valued at $54,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of AnaptysBio by 48.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,749 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 898 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of AnaptysBio in the first quarter valued at about $110,000. Lazard Asset Management LLC lifted its position in AnaptysBio by 60.1% during the 4th quarter. Lazard Asset Management LLC now owns 3,589 shares of the biotechnology company’s stock worth $124,000 after buying an additional 1,347 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale grew its holdings in AnaptysBio by 10.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 5,300 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 500 shares during the last quarter.

AnaptysBio Company Profile (Get Rating)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Recommended Stories

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.